Selepressin, a New V1A Receptor Agonist
Authors:
- Stéphane P. MilanoSMStéphane P. Milano
- Marie HenrikssonMHMarie Henriksson
- Torsten M. ReinheimerTRTorsten M. Reinheimer
- 1 June 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Shock
- Vol. 39 (6) , 533-538
Abstract
Selepressin is a new selective vasopressin V1a agonist for treatment of vasodilatory hypotension in shock. Its effect on coronary and aortic blood flow, hemodynamics, and electrocardiogram as an indication of drug safety in healthy dogs was compared with arginine vasopressin (AVP). Eight dogs were fasted, anesthetized, intubated, and ventilated. Following thoracotomy, coronary and aortic blood flows were monitored, left ventricular and peripheral arterial blood pressures were measured, and electrocardiogram was recorded. Selepressin or AVP was administered by dose-escalating infusions (1-300, 0.3-100 ng · kg(-1) · min(-1), respectively). Drug formulation analysis and plasma bioanalysis confirmed exposure. For each dose level, hemodynamic parameters, drug potency, and efficacy were determined. Selepressin and AVP induced a similar increase in mean blood pressure (+13% to 18%), a moderate decrease in aortic blood flow (-40% to 45%), and a slight decrease in coronary blood flow (-16% to 22%). These vasopressors displayed similar hemodynamic characteristics, with peripheral vasoconstriction and decreased aortic blood flow being more pronounced than the increase in coronary resistance and decrease in coronary blood flow. Importantly, selepressin bore no relevant coronary ischemic liability, suggesting that V1a receptor agonists are a potential pharmacological target for treatment of vasodilatory hypotension in shock.Keywords
This publication has 21 references indexed in Scilit:
- Synthesis and in vitro Pharmacological Profile of Potent and Selective Peptidic V1a Receptor Agonists.2009
- Arginine vasopressin: a promising rescue drug in the treatment of uncontrolled haemorrhagic shockBest Practice & Research Clinical Anaesthesiology, 2008
- Vasopressin analogues in the treatment of shock states: potential pitfallsBest Practice & Research Clinical Anaesthesiology, 2008
- Selective V1a receptor agonist FE 202158 reverses platelet-activating factor-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in ratsCritical Care, 2008
- Selective V1a receptor agonists in experimental septic shockCritical Care, 2007
- Bench-to-bedside review: Sepsis is a disease of the microcirculationCritical Care, 2004
- Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs*Critical Care Medicine, 2003
- The cellular basis of septic shockCritical Care Nursing Clinics of North America, 2003
- EFFECT OF CONIVAPTAN, A COMBINED VASOPRESSIN V1a AND V2 RECEPTOR ANTAGONIST, ON VASOPRESSIN-INDUCED CARDIAC AND HAEMODYNAMIC CHANGES IN ANAESTHETISED DOGSPharmacological Research, 2002
- Felypressin-induced reduction in coronary blood flow and myocardial tissue oxygen tension during anesthesia in dogsCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1999